Background: Serogroup B meningococcal disease caused 7 US university outbreaks during 2013-2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal carriage. MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a college outbreak. We investigated MenB-FHbp impact on meningococcal carriage. Methods: Four cross-sectional surveys were conducted in conjunction with MenB-FHbp vaccination campaigns. Questionnaires and oropharyngeal swabs were collected from students. Specimens were evaluated using culture, slide agglutination, real-time polymerase chain reaction (rt-PCR), and whole genome sequencing. Adjusted prevalence ratios (aPRs) were calculated using generalized estimating equations. Results: During each survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-PCR. The outbreak strain (ST-9069) was not detected during the initial survey; 1 student carried ST-9069 in the second and third surveys. No carriage reduction was observed over time or with more MenB-FHbp doses. In total, 615 students participated in multiple surveys: 71% remained noncarriers, 8% cleared carriage, 15% remained carriers, and 7% acquired carriage. Ten students acquired serogroup B carriage: 3 after 1 MenB-FHbp dose, 4 after 2 doses, and 3 after 3 doses. Smoking (aPR, 1.3; 95% confidence interval [CI], 1.1-1.5) and male sex (aPR, 1.3; 95% CI, 1.1-1.5) were associated with increased meningococcal carriage. Conclusions: Carriage prevalence on campus remained stable, suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage acquisition. This reinforces the need for high vaccination coverage to protect vaccinated individuals and chemoprophylaxis for close contacts during outbreaks. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Serogroup B meningococcal disease caused 7 US university outbreaks during 2013-2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal carriage. MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a college outbreak. We investigated MenB-FHbp impact on meningococcal carriage. Methods: Four cross-sectional surveys were conducted in conjunction with MenB-FHbp vaccination campaigns. Questionnaires and oropharyngeal swabs were collected from students. Specimens were evaluated using culture, slide agglutination, real-time polymerase chain reaction (rt-PCR), and whole genome sequencing. Adjusted prevalence ratios (aPRs) were calculated using generalized estimating equations. Results: During each survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-PCR. The outbreak strain (ST-9069) was not detected during the initial survey; 1 student carried ST-9069 in the second and third surveys. No carriage reduction was observed over time or with more MenB-FHbp doses. In total, 615 students participated in multiple surveys: 71% remained noncarriers, 8% cleared carriage, 15% remained carriers, and 7% acquired carriage. Ten students acquired serogroup B carriage: 3 after 1 MenB-FHbp dose, 4 after 2 doses, and 3 after 3 doses. Smoking (aPR, 1.3; 95% confidence interval [CI], 1.1-1.5) and male sex (aPR, 1.3; 95% CI, 1.1-1.5) were associated with increased meningococcal carriage. Conclusions: Carriage prevalence on campus remained stable, suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage acquisition. This reinforces the need for high vaccination coverage to protect vaccinated individuals and chemoprophylaxis for close contacts during outbreaks. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: C C Blackwell; D M Weir; V S James; W T Todd; N Banatvala; A K Chaudhuri; H G Gray; E J Thomson; R J Fallon Journal: Epidemiol Infect Date: 1990-04 Impact factor: 2.451
Authors: Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark Journal: Pediatrics Date: 2015-05 Impact factor: 7.124
Authors: Sema Mandal; Henry M Wu; Jessica R MacNeil; Kimberly Machesky; Jocelyn Garcia; Brian D Plikaytis; Kim Quinn; Larry King; Susanna E Schmink; Xin Wang; Leonard W Mayer; Thomas A Clark; James R Gaskell; Nancy E Messonnier; Mary DiOrio; Amanda C Cohn Journal: Clin Infect Dis Date: 2013-04-17 Impact factor: 9.079
Authors: Hope H Biswas; George S Han; Kristen Wendorf; Kathleen Winter; Jennifer Zipprich; Tara Perti; Linda Martinez; Aileen Arellano; Jennifer L Kyle; Peng Zhang; Kathleen Harriman Journal: MMWR Morb Mortal Wkly Rep Date: 2016-05-27 Impact factor: 17.586
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan Journal: Hum Vaccin Immunother Date: 2018-04-30 Impact factor: 3.452
Authors: Elizabeth M La; Sandra E Talbird; Koren V Kanadanian; Liping Huang; Joel Fain; Amit Srivastava Journal: Hum Vaccin Immunother Date: 2019-01-16 Impact factor: 3.452
Authors: Lucy A McNamara; Jennifer Dolan Thomas; Jessica MacNeil; How Yi Chang; Michael Day; Emily Fisher; Stacey Martin; Tasha Poissant; Susanna E Schmink; Evelene Steward-Clark; Laurel T Jenkins; Xin Wang; Anna Acosta Journal: J Infect Dis Date: 2017-11-27 Impact factor: 5.226
Authors: Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer Journal: Vaccine Date: 2020-08-30 Impact factor: 3.641